Larimar Therapeutics, Inc. (LRMR)
$4.09+$0.04 (+0.99%) Today
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market purchase | 1 | 50,000 | $167K |
20 Form 4 filings on record, the earliest from May 13, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Thomas Edward Hamilton | Open-market purchase | Common Stock | 50,000 | $3.34 | $167K | |
| James E. Flynn - Director | Grant or award | Stock Option (Right to Buy) | 55,150 | $0.00 | - | |
| Jonathan S. Leff | Grant or award | Stock Option (Right to Buy) | 55,150 | $0.00 | - | |
| Jeffrey W. Sherman | Grant or award | Stock Option (Right to Buy) | 55,150 | $0.00 | - | |
| Joseph Truitt | Grant or award | Stock Option (Right to Buy) | 55,150 | $0.00 | - | |
| Frank E. Thomas | Grant or award | Stock Option (Right to Buy) | 55,150 | $0.00 | - | |
| Thomas Edward Hamilton | Grant or award | Stock Option (Right to Buy) | 55,150 | $0.00 | - | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 1,084,010 | $5.00 | $5.42M | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 1,084,012 | $5.00 | $5.42M | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 831,978 | $5.00 | $4.16M | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 2,000,000 | $5.00 | $10.00M | |
| Thomas Edward Hamilton | Open-market purchase | Common Stock | 100,000 | $5.00 | $500K | |
| Frank E. Thomas | Open-market purchase | Common Stock | 5,000 | $5.00 | $25K | |
| Jeffrey W. Sherman | Open-market purchase | Common Stock | 5,000 | $5.00 | $25K | |
 Gopi Shankar - Officer | Grant or award | Common Stock | 25,637 | $0.00 | - | |
| Gopi Shankar - Officer | Grant or award | Stock Option (Right to Buy) | 153,822 | $0.00 | - | |
 Russell Clayton - Officer | Grant or award | Common Stock | 25,637 | $0.00 | - | |
| Russell Clayton - Officer | Grant or award | Stock Option (Right to Buy) | 153,822 | $0.00 | - | |
| Carole Ben-Maimon - Officer | Grant or award | Common Stock | 100,100 | $0.00 | - | |
| Carole Ben-Maimon - Officer | Grant or award | Stock Option (Right to Buy) | 600,600 | $0.00 | - | |
 Michael Celano - Officer | Grant or award | Common Stock | 37,604 | $0.00 | - | |
| Michael Celano - Officer | Grant or award | Stock Option (Right to Buy) | 225,622 | $0.00 | - | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 3,387,529 | $3.20 | $10.84M | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 3,387,539 | $3.20 | $10.84M | |
| James E. Flynn - Director | Open-market purchase | Common Stock | 2,599,932 | $3.20 | $8.32M | |
| Frank E. Thomas - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
| Jeffrey W. Sherman - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
| Jonathan S. Leff - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - | |
| James E. Flynn - Director | Grant or award | Stock Option (Right to Buy) | 19,000 | $0.00 | - |
Larimar Therapeutics, Inc. (LRMR) had 1 insider filing in the last 90 days, with the most recent on 2026-07-08. The full record for LRMR runs to 20 Form 4 filings, the earliest from 2025-05-13. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
1 insider purchase of LRMR was filed in the last 90 days, totaling $167K.
No insider sales of LRMR were filed in the last 90 days.
This page tracks LRMR Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add LRMR to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
